Semglee (insulin glargine-yfgn) is a long-acting basal insulin used once daily to control blood sugar in adults and children with type 1 or type 2 diabetes. In 2021 the FDA designated Semglee as the first interchangeable biosimilar of Lantus, allowing pharmacists to substitute it directly in most states. Clinically, Semglee performs the same as Lantus at a lower list price.
What Makes Semglee “Interchangeable”
Biosimilars are biologic drugs highly similar to an already-approved reference product. The FDA grants an “interchangeable” designation only when additional clinical data show that switching back and forth does not change safety or effectiveness. Semglee was the first insulin to meet this bar, followed by others in later years. For patients and pharmacies the practical meaning is simple: in most states, Semglee can be substituted for Lantus at the counter, the way a generic is substituted for a brand drug.
This matters because insulin prices have been a persistent problem in the United States. For a broader look at medication choices in diabetes, see our treatment overview.
How Semglee Works
Insulin glargine is a basal insulin analog modified to form microprecipitates in the subcutaneous tissue. These precipitates slowly dissolve and release insulin into the bloodstream over roughly 24 hours, giving a relatively flat profile with no pronounced peak. This flat background insulin mirrors the steady insulin that the pancreas normally produces between meals and overnight.
Semglee is not used to cover meals. It is almost always paired with a rapid-acting insulin for meals, oral medications, or both. For help interpreting the A1C number you and your doctor are tracking, the A1C levels guide explains what different numbers mean.
Who Uses Semglee
The FDA approved Semglee for:
- Adults with type 1 or type 2 diabetes needing basal insulin
- Children age 6 and older with type 1 diabetes
- People switching from Lantus or other basal insulins with appropriate clinical supervision
It is often chosen as a first basal insulin for patients with type 2 diabetes whose A1C remains above target on oral agents or a GLP-1 receptor agonist, or as a cost-conscious alternative to branded Lantus.
Onset, Peak, and Duration
| Insulin | Onset | Peak | Duration |
|---|---|---|---|
| Semglee / Lantus (glargine U-100) | 1 to 2 hr | Minimal | ~24 hr |
| Toujeo (glargine U-300) | 6 hr | Minimal | Up to 36 hr |
| Tresiba (degludec) | 1 hr | Minimal | 42 hr |
| Levemir (detemir) | 1 to 2 hr | Minimal | 14 to 20 hr |
| NPH (isophane) | 1 to 2 hr | 4 to 12 hr | 14 to 24 hr |
How Semglee Is Dosed
Dosing is individualized but follows established starting points:
- Insulin-naive type 2 diabetes: 10 units once daily or 0.1 to 0.2 units per kilogram per day
- Type 1 diabetes: roughly 50 percent of the total daily insulin dose delivered as basal
- Switching from once-daily Lantus: unit-for-unit conversion
- Switching from NPH twice daily: total NPH dose reduced by about 20 percent for once-daily glargine
Dose is titrated every 3 days based on fasting glucose — often in 2-unit steps up or down — until the target (commonly 80 to 130 mg/dL) is reached without nocturnal hypoglycemia.
Injection Technique
Semglee is injected into the subcutaneous fat of the abdomen, thigh, or upper arm at the same time each day. Rotate within a region from injection to injection. Never mix Semglee with any other insulin in the same syringe — mixing destroys its prolonged-release property.
It is available as a 10 mL vial and as the prefilled Semglee pen (3 mL, 1-unit dose increments). The pen is convenient for travel and for visually impaired users.
Common Side Effects
- Hypoglycemia
- Injection site redness, itching, or swelling
- Weight gain (typically modest after starting basal insulin)
- Lipohypertrophy with repeated same-site injection
- Rare allergic reactions
Serious Warnings
Never Share Pens or Needles
Sharing insulin pens, even with a new needle, can transmit blood-borne pathogens. Each patient must use their own Semglee pen.
Hypoglycemia
Severe hypoglycemia is the most important risk of any insulin. Because Semglee acts slowly over 24 hours, overnight lows are a particular concern. Family members should know how to recognize symptoms and use glucagon.
Hypokalemia
Insulin shifts potassium into cells and can lower serum potassium. Patients on diuretics, with kidney disease, or with pre-existing low potassium need closer monitoring.
Fluid Retention
Combining insulin with a thiazolidinedione such as pioglitazone raises the risk of fluid overload and heart failure.
Hypersensitivity
Severe allergic reactions, though rare, can occur. Stop Semglee and seek emergency care for widespread rash, facial swelling, or breathing difficulty.
Drug Interactions
Medications that can affect insulin requirements include beta-blockers (mask hypoglycemia symptoms), corticosteroids (raise insulin need), thiazide diuretics (raise insulin need), atypical antipsychotics, and alcohol (can prolong hypoglycemia). Keep your full medication list current with your pharmacist.
Cost and Insurance Coverage
Semglee launched at roughly 65 percent off the list price of Lantus. Actual out-of-pocket cost depends on insurance:
- Commercial insurance: usually covered at the same or a preferred tier compared with Lantus
- Medicare Part D: capped at $35 per month for covered insulins under the Inflation Reduction Act
- Manufacturer savings programs: Viatris offers a savings card for eligible commercial patients
- Uninsured cash price: significantly lower than Lantus at most retail pharmacies
Storage and Handling
- Unopened vials and pens: refrigerate at 36 to 46 degrees Fahrenheit until expiration date
- In-use: room temperature below 86 degrees for up to 28 days, then discard
- Do not freeze; do not expose to direct sunlight or heat
- Inspect before use — glargine is clear and colorless; discard if cloudy or particulate
Semglee vs. Other Basal Insulins
| Insulin | Concentration | Frequency | Key Feature |
|---|---|---|---|
| Semglee / Lantus | 100 units/mL | Once daily | Reference glargine; flat 24-hr profile |
| Toujeo | 300 units/mL | Once daily | Smaller injection volume, longer tail |
| Tresiba | 100 or 200 units/mL | Once daily | 42-hour duration; flexible timing |
| Levemir | 100 units/mL | Once or twice daily | Shorter duration than glargine |
| Basaglar | 100 units/mL | Once daily | Follow-on glargine (not interchangeable) |
When to Contact Your Care Team
- Severe hypoglycemia, especially overnight
- Repeated fasting glucose above 200 mg/dL or below 70 mg/dL
- Planning pregnancy, major surgery, or an illness with vomiting
- New injection site lump or pain
- Questions about pharmacy substitution to or from Semglee
- Suspected allergic reaction
The Bottom Line
Semglee is a clinically equivalent, lower-cost alternative to Lantus and a landmark product as the first FDA-designated interchangeable biosimilar insulin. For most patients the switch is seamless and happens at the pharmacy counter, with dosing and side effects matching Lantus. Ask your clinician and pharmacist whether Semglee makes sense for your plan — and continue the lifestyle foundation of balanced eating, activity, weight management, and sleep that every diabetes medication is designed to support.
